Page last updated: 2024-12-08

4'-galactooligosaccharide

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

4'-galactooligosaccharide: structure given in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

galactooligosaccharide : An oligosaccharide comprised of galactose residues. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Cross-References

ID SourceID
PubMed CID165512
SCHEMBL ID12362685
MeSH IDM0195792

Synonyms (13)

Synonym
4'-galactooligosaccharide
d-glucose, o-beta-d-galactopyranosyl-(1-4)-o-beta-d-galactopyranosyl-(1-4)-
(2r,3r,4r,5r)-4-[(2s,3r,4r,5r,6r)-3,4-dihydroxy-6-(hydroxymethyl)-5-[(2s,3r,4s,5r,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxyoxan-2-yl]oxy-2,3,5,6-tetrahydroxyhexanal
o-beta-d-galactopyranosyl-(1-4)-o-beta-d-galactopyranosyl-(1-4)-d-glucose
b8cw1b3f6r ,
4'-galacto-oligosaccharide
galactooligosaccharide
unii-b8cw1b3f6r
SCHEMBL12362685
DTXSID60276547
o-.beta.-d-galactopyranosyl-(1->4)-o-.beta.-d-galactopyranosyl-(1->4)-d-glucose
mucotriose
d-glucose, o-.beta.-d-galactopyranosyl-(1->4)-o-.beta.-d-galactopyranosyl-(1->4)-

Research Excerpts

Toxicity

ExcerptReferenceRelevance
" The no observed adverse effect level (NOAEL) of GOS was at least 2000 mg/kg/day in both males and females."( Safety of a novel galacto-oligosaccharide: Genotoxicity and repeated oral dose studies.
Kaneko, K; Kobayashi, T; Ohyama, W; Onoue, M; Uchida, K; Yasutake, N, 2009
)
0.35

Bioavailability

ExcerptReferenceRelevance
"The effect of different levels (0, 10 and 20%) of O-beta-D-galactopyranosyl-(1-4)-O-beta-D-galactopyranosyl-(1-4)-D- glucose (4'-GL) on the bioavailability of sodium and potassium was studied in 18 male rats."( 4'-galactooligosaccharide affects sodium and potassium metabolism in rats.
Hayashi, M; Ito, O; Kakiichi, N; Kamata, S; Shimazaki, Y; Shitara, A; Taki, S; Ueda, F, 1991
)
1.72
" The aim of our study was to evaluate iron bioavailability of YCF relative to prebiotic and AA concentrations."( In vitro assessment of iron availability from commercial Young Child Formulae supplemented with prebiotics.
Christides, T; Ganis, JC; Sharp, PA, 2018
)
0.48
"We used the in vitro digestion/Caco-2 cell model to measure iron bioavailability from 4 commercially available YCF with approximately equal amounts of iron, but varying amounts of: AA and the prebiotics fructo- and galacto-oligosaccharides."( In vitro assessment of iron availability from commercial Young Child Formulae supplemented with prebiotics.
Christides, T; Ganis, JC; Sharp, PA, 2018
)
0.48
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (31)

TimeframeStudies, This Drug (%)All Drugs %
pre-19900 (0.00)18.7374
1990's3 (9.68)18.2507
2000's6 (19.35)29.6817
2010's20 (64.52)24.3611
2020's2 (6.45)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 11.33

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index11.33 (24.57)
Research Supply Index3.76 (2.92)
Research Growth Index5.09 (4.65)
Search Engine Demand Index0.00 (26.88)
Search Engine Supply Index0.00 (0.95)

This Compound (11.33)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials9 (27.27%)5.53%
Reviews3 (9.09%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other21 (63.64%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]